Insulin-like growth factor-I treatment to enhance renal function in advanced chronic renal failure

Fernando Custodio Fervenza, Michael M. Friedlaender, John O. Ike, Ralph Rabkin

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Because of the potential for IGF-I to enhance renal function in advanced chronic renal failure (CRF) we set out to determine whether IGF-I can induce a sustained increase in renal function in patients with near end-stage renal failure. To this end we first examined the impact of CRF on the pharmacokinetics of IGF-I and then we examined the effect of prolonged IGF-I treatment on the renal function of patients with an average GFR of 17mL/min/1.73m2. Interestingly the metabolic clearance rate of IGF-I in CRF subjects was similar to that in normal subjects even though the total serum IGF-I levels rose to higher maximum levels. This increase was due to a reduced volume of IGF-I distribution, a consequence of the elevated serum IGF binding proteins in CRF subjects. Treatment with IGF-I (60 mg/kg twice daily sc) for 31 days resulted in a 14% and 18% increase in the inulin and PAH clearances respectively (n = 6 patients). These parameters returned to basal levels on stopping treatment. Serum immunoreactive IGFBP-3 levels fell and IGFBP-2 and -3 levels rose during IGF-I therapy. Adverse effects were mild, of short duration and easily manageable. Thus IGF-I pharmacokinetics are largely unchanged in CRF and the administration of IGF-I produces a modest improvement in the GFR. These results appear to justify more extensive examination of the therapeutic role of IGF-I in the treatment of CRF.

Original languageEnglish (US)
Pages (from-to)349-356
Number of pages8
JournalRenal Failure
Volume20
Issue number2
StatePublished - 1998
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Chronic Kidney Failure
Kidney
Therapeutics
Insulin-Like Growth Factor Binding Protein 3
Pharmacokinetics
Metabolic Clearance Rate
Insulin-Like Growth Factor Binding Protein 2
Insulin-Like Growth Factor Binding Proteins
Inulin
Serum
Blood Proteins

Keywords

  • Chronic renal failure
  • Insulin-like growth factor

ASJC Scopus subject areas

  • Nephrology

Cite this

Insulin-like growth factor-I treatment to enhance renal function in advanced chronic renal failure. / Fervenza, Fernando Custodio; Friedlaender, Michael M.; Ike, John O.; Rabkin, Ralph.

In: Renal Failure, Vol. 20, No. 2, 1998, p. 349-356.

Research output: Contribution to journalArticle

Fervenza, Fernando Custodio ; Friedlaender, Michael M. ; Ike, John O. ; Rabkin, Ralph. / Insulin-like growth factor-I treatment to enhance renal function in advanced chronic renal failure. In: Renal Failure. 1998 ; Vol. 20, No. 2. pp. 349-356.
@article{afa33c549bea434fb3597fe202047390,
title = "Insulin-like growth factor-I treatment to enhance renal function in advanced chronic renal failure",
abstract = "Because of the potential for IGF-I to enhance renal function in advanced chronic renal failure (CRF) we set out to determine whether IGF-I can induce a sustained increase in renal function in patients with near end-stage renal failure. To this end we first examined the impact of CRF on the pharmacokinetics of IGF-I and then we examined the effect of prolonged IGF-I treatment on the renal function of patients with an average GFR of 17mL/min/1.73m2. Interestingly the metabolic clearance rate of IGF-I in CRF subjects was similar to that in normal subjects even though the total serum IGF-I levels rose to higher maximum levels. This increase was due to a reduced volume of IGF-I distribution, a consequence of the elevated serum IGF binding proteins in CRF subjects. Treatment with IGF-I (60 mg/kg twice daily sc) for 31 days resulted in a 14{\%} and 18{\%} increase in the inulin and PAH clearances respectively (n = 6 patients). These parameters returned to basal levels on stopping treatment. Serum immunoreactive IGFBP-3 levels fell and IGFBP-2 and -3 levels rose during IGF-I therapy. Adverse effects were mild, of short duration and easily manageable. Thus IGF-I pharmacokinetics are largely unchanged in CRF and the administration of IGF-I produces a modest improvement in the GFR. These results appear to justify more extensive examination of the therapeutic role of IGF-I in the treatment of CRF.",
keywords = "Chronic renal failure, Insulin-like growth factor",
author = "Fervenza, {Fernando Custodio} and Friedlaender, {Michael M.} and Ike, {John O.} and Ralph Rabkin",
year = "1998",
language = "English (US)",
volume = "20",
pages = "349--356",
journal = "Renal Failure",
issn = "0886-022X",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - Insulin-like growth factor-I treatment to enhance renal function in advanced chronic renal failure

AU - Fervenza, Fernando Custodio

AU - Friedlaender, Michael M.

AU - Ike, John O.

AU - Rabkin, Ralph

PY - 1998

Y1 - 1998

N2 - Because of the potential for IGF-I to enhance renal function in advanced chronic renal failure (CRF) we set out to determine whether IGF-I can induce a sustained increase in renal function in patients with near end-stage renal failure. To this end we first examined the impact of CRF on the pharmacokinetics of IGF-I and then we examined the effect of prolonged IGF-I treatment on the renal function of patients with an average GFR of 17mL/min/1.73m2. Interestingly the metabolic clearance rate of IGF-I in CRF subjects was similar to that in normal subjects even though the total serum IGF-I levels rose to higher maximum levels. This increase was due to a reduced volume of IGF-I distribution, a consequence of the elevated serum IGF binding proteins in CRF subjects. Treatment with IGF-I (60 mg/kg twice daily sc) for 31 days resulted in a 14% and 18% increase in the inulin and PAH clearances respectively (n = 6 patients). These parameters returned to basal levels on stopping treatment. Serum immunoreactive IGFBP-3 levels fell and IGFBP-2 and -3 levels rose during IGF-I therapy. Adverse effects were mild, of short duration and easily manageable. Thus IGF-I pharmacokinetics are largely unchanged in CRF and the administration of IGF-I produces a modest improvement in the GFR. These results appear to justify more extensive examination of the therapeutic role of IGF-I in the treatment of CRF.

AB - Because of the potential for IGF-I to enhance renal function in advanced chronic renal failure (CRF) we set out to determine whether IGF-I can induce a sustained increase in renal function in patients with near end-stage renal failure. To this end we first examined the impact of CRF on the pharmacokinetics of IGF-I and then we examined the effect of prolonged IGF-I treatment on the renal function of patients with an average GFR of 17mL/min/1.73m2. Interestingly the metabolic clearance rate of IGF-I in CRF subjects was similar to that in normal subjects even though the total serum IGF-I levels rose to higher maximum levels. This increase was due to a reduced volume of IGF-I distribution, a consequence of the elevated serum IGF binding proteins in CRF subjects. Treatment with IGF-I (60 mg/kg twice daily sc) for 31 days resulted in a 14% and 18% increase in the inulin and PAH clearances respectively (n = 6 patients). These parameters returned to basal levels on stopping treatment. Serum immunoreactive IGFBP-3 levels fell and IGFBP-2 and -3 levels rose during IGF-I therapy. Adverse effects were mild, of short duration and easily manageable. Thus IGF-I pharmacokinetics are largely unchanged in CRF and the administration of IGF-I produces a modest improvement in the GFR. These results appear to justify more extensive examination of the therapeutic role of IGF-I in the treatment of CRF.

KW - Chronic renal failure

KW - Insulin-like growth factor

UR - http://www.scopus.com/inward/record.url?scp=0031924079&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031924079&partnerID=8YFLogxK

M3 - Article

C2 - 9574462

AN - SCOPUS:0031924079

VL - 20

SP - 349

EP - 356

JO - Renal Failure

JF - Renal Failure

SN - 0886-022X

IS - 2

ER -